ReviewDrugs2015
Pasireotide in Acromegaly: A Review.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Trial
- Review
- Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar.Case reports in endocrinology · 2025Article
- Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.JCEM case reports · 2024Article
- Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal.Frontiers in endocrinology · 2024Review
- Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.The Journal of clinical endocrinology and metabolism · 2023Article
- Recent advances in PLGA micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistantFrontiers in bioengineering and biotechnology · 2022Review
- Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.ACS biomaterials science & engineering · 2021Review
- Pasireotide in the Personalized Treatment of Acromegaly.Frontiers in endocrinology · 2021Review
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.Reviews in endocrine & metabolic disorders · 2019Review
- Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells.Journal of the Endocrine Society · 2018Article
- Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches.BMJ case reports · 2018Article
- Novel Somatostatin Receptor Ligands Therapies for Acromegaly.Frontiers in endocrinology · 2018Review
- Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study.International journal of endocrinology · 2018Article
- Impact of the Hydration States of Polymers on Their Hemocompatibility for Medical Applications: A Review.International journal of molecular sciences · 2017Review
- Blood Glucose and Insulin Concentrations after Octreotide Administration in Horses With Insulin Dysregulation.Journal of veterinary internal medicine · 2017Article
- Review
- Pasireotide: a novel treatment for patients with acromegaly.Drug design, development and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pasireotide (Signifor(®), Signifor(®) LAR) is a somatostatin analogue recently approved for the treatment of acromegaly. Unlike the first-generation agents, octreotide and lanreotide, which bind preferentially to somatostatin receptor (SSTR)-2, pasireotide binds to multiple SSTRs. This article reviews the clinical use and summarizes the pharmacological properties of intramuscular pasireotide in the treatment of acromegaly. The efficacy of pasireotide 40 mg every 28 days was superior to that of intramuscular octreotide 20 mg every 28 days with regard to biochemical control in a 12-month, phase III trial in medically naive patients. Similarly, in a 6-month, phase III trial in patients with acromegaly inadequately controlled with somatostatin analogues for at least 6 months, the efficacy of pasireotide 40 or 60 mg was superior to that of continued octreotide 30 mg or lanreotide autogel 120 mg (each drug was administered once every 28 days) with regard to biochemical control. The tolerability profile of intramuscular pasireotide is generally similar to that of first-generation agents, except for a higher incidence of hyperglycaemia-related adverse events with pasireotide. In clinical trials, the risk of developing pasireotide-associated hyperglycaemia was numerically greater in patients categorized as diabetic or prediabetic at baseline than in those with normal glucose tolerance. Careful monitoring of glycaemic status is required prior to and during pasireotide treatment and antidiabetic therapy should be commenced as indicated. Thus, in the treatment of acromegaly, pasireotide may be a more effective somatostatin analogue than other approved agents of the same class; however, the increased risk of hyperglycaemia needs to be considered and proactively managed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.